Fig. 4: Anti-ofCS antibody therapies elicit anti-tumor activity in vivo.
From: Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate
Tumor burden (mean +/− SEM mm3), body weight and survival curves of mice. a Xenografted with Karpas299 and treated with ABD-C9-scFv ADC, ADC control, or PBS (n = 5). b Allografted with colorectal cancer cells CT26 and treated with ABD-tandem-C9 (ABD-T-C9) or ADC control (n = 7). c Xenografted with patient-derived-xenograft (PDX) sarcoma cells and received F3 or F8-based ADCs (n = 6). d Individual tumor burden (mm3) of mice allografted with CT26 cells and treated with C9-scFv ADC, a lysine-conjugated semi-inactivated C9-ADC, or PBS (n = 7). e Tumor burden (mean +/− SEM mm3) of mice xenografted with melanoma A375 wild type (WT) or Chst11 knock-out (KO), treated with ABD-C9-scFv ADC, ADC control, or PBS (n = 5). f Analysis of tissues from (e), stained with C9-scFv2 (red) and DAPI for nuclei (blue). g Tumor burden (mean +/− SEM mm3) of cured mice from (b), re-challenged with CT26 cells, compared to naive mice injected with cells for the first time (PBS). h Same as in (e), but mice were allografted with CT26 cells and treated with T-C9 ADC alone, in combination with PD1, PD1 alone, or PBS (n = 7). i Immunoprofiling of tumor suspensions from mice treated as in (h), counting CD45+/CD4+ and CD45+/CD8+ populations (PDL-1, n = 2), PDL-1 + T-C9 ADC, T-C9, ADC, and PBS, n = 3)). with triplicate samples. Two-tailed nested t-test compared means and non-significant results were labeled “ns”. j TNFalpha levels from pooled plasma of mice in (i) measured in ELISA in duplicates. Levels in PBS and PD1 groups were below detection limit and marked with an asterisk. k Similar to (a), but mice received 4T1 cells subcutaneously (s.c), and were treated with T-C9-aCD3 with or without anti-CTLA4 checkpoint inhibitor and T-C9 as control (n = 6). l Similar to (e), but mice received 4T1 cells in the mammary fat pad (mfp) and were treated with ABD-T-C9-aCD3 and ABD-T-C9 as control (n = 5). m Immune cell counts (CD3+, CD8+, and CD4+) of 4T1 mfp tumors (n = 2) after three treatments with PBS, aCD3, or T-C9-aCD3. Replicate staining was performed (n = 4) and two-tailed nested t-test was applied to compare groups. Red arrows indicate days of treatment. Source data are provided as a Source data file.
